Interstitial pneumonitis associated with dasatinib: two case reports and literature review

Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib

“…BALF analyses mostly showed lymphocytic predominance (2,5,6,8). The CD4/CD8 ratio in our case was 2.12; however, the CD4/CD8 ratio was rarely mentioned in previous reports of dasatinib-induced ILD.…”

“…No mortality has been reported thus far ( 5 ). Furthermore, the successful re-administration of dasatinib, at lower doses or with corticosteroids, has been reported ( 2 , 5 , 8 ). In one case, the ILD resolved with corticosteroid treatment without the discontinuation of dasatinib ( 2 ).…”

“…There have been few reports on dasatinib-induced ILD (2,(5)(6)(7)(8). However, they appear to show some common features: (a) occurrence long after the use of dasatinib (length of time between starting dasatinib and the onset of ILD varies widely), (b) lymphocyte-predominant inflammation, (c) good response to steroid treatment, and (d) tolerability to re-challenge.…”

“…Pulmonary hypertension develops less often in 0.3-5% of patients ( 1 - 4 ). ILD is not so well described, but seems to be more common than is generally perceived ( 2 , 4 , 5 ). We herein describe a case of dasatinib-induced ILD with cellular non-specific interstitial pneumonia (NSIP) histology, which developed 7 years after the initiation of dasatinib treatment, but which responded well to corticosteroids.…”

Drug‐induced interstitial lung disease associated with dasatinib coinciding with active tuberculosis

“…Dasatinib has been increasingly used in the treatment of CML. Drug‐induced ILD associated with dasatinib exhibiting ground‐glass opacities and interlobular septal thickening has been reported in two case series [2,3], while pleural effusion being the most common AE. Dasatinib‐induced ILD occurs in a dose‐dependent manner, as the ILD improved after interruption of dasatinib, and was well controlled with a dose reduction in 75% of such cases [2].…”